Many patients using GLP-1 medications such as semaglutide (Ozempic®, Wegovy®) or tirzepatide (Mounjaro®, Zepbound®) eventually experience a weight-loss plateau. This is normal and happens because the body adapts to weight loss and lower calorie intake.
As weight decreases, the body naturally adjusts by:
These changes can temporarily slow or stop weight loss—even when patients continue healthy habits.
Muscle helps maintain a healthy metabolism. Losing too much lean muscle during weight loss can slow calorie burning.
Strategies may include:
Goal: Maintain muscle to support continued fat loss.
Over time, the body adapts to lower calorie intake. Small changes in nutrition can help restart progress.
Examples include:
Goal: Support metabolism while maintaining a sustainable calorie deficit.
Providers may evaluate:
Some patients ask about peptides such as sermorelin or MOTS-c. These are not FDA-approved for weight management, and research in people is limited. Your provider can discuss whether any additional option is appropriate for you.
Important to Remember
Weight-loss plateaus are very common and expected during long-term weight management. Talk with your provider about muscle preservation, nutrition adjustments, and metabolic health.
This article is for general information only and is not medical advice. Compounded medications are not FDA-approved, and the FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Individual results vary.
